Gabify Lands $175K Pre Seed Funding to Innovate Neurodevelopmental Care with AI

Healthtech startup Gabify has raised $175,000 in a pre-seed funding round led by Inflection Point Ventures (IPV), marking a significant step forward for AI neurodevelopmental care in India. The company also secured ₹25 lakhs under the Nidhi Seed Support Scheme by GHRTBI, a government-backed incubator supporting high-potential startups. The fresh capital will be used for clinical validation, technology upgrades, and team expansion.

Gabify is part of the fourth cohort of IPV IdeaSchool, a cohort-based incubator programme for early-stage startups. The initiative has already supported several emerging ventures across five cohorts, building a strong pipeline of innovation-led businesses.

Building AI Neurodevelopmental Care in India

Gabify is positioning itself at the forefront of AI neurodevelopmental care in India. It has built the country’s first fully hosted speech and neurodevelopmental SaaS ecosystem. The platform offers end-to-end AI-driven screening and therapy for conditions such as Autism and ADHD.

The startup uses a dual AI system combining voice and vision analysis. This enables a deeper understanding of speech patterns, facial expressions, eye movement, and behaviour. The platform evaluates over 189 clinically validated parameters aligned with DSM 5 and CARS standards.

A human-in-the-loop approach ensures that all AI-generated outputs are reviewed by clinicians. This helps maintain high accuracy while improving efficiency. The system is multilingual and designed for low-bandwidth environments, making it suitable for rural India with potential for global expansion.

Scaling Access and Clinical Efficiency

Gabify claims to reduce assessment time by up to 70%. This allows clinicians to handle more cases without compromising on quality. During its private beta phase, the platform was tested across more than 35 preschool and daycare centres in India.

It is already being adopted by schools, hospitals, private clinics, and non-profits. The startup has also gained recognition through programmes such as UNDP Youth Co-Lab and several global conferences.

According to Ankur Mittal, Co-founder of Inflection Point Ventures, early intervention in neurodevelopmental conditions remains underserved. He noted that Gabify’s blend of AI and clinical validation can reduce diagnosis timelines and improve outcomes at scale.

Also Read: ChatGPT Comes to Apple CarPlay: Why This Update Could Change the Way We Drive and Search on the Go

Growth Vision and Market Opportunity

Gabify aims to impact one million children by 2028 through B2B, B2C, and CSR-driven rollouts. Founder and CEO Sahil Chopra emphasised that the mission is to ensure no child is left behind due to delayed diagnosis or lack of access.

The founding team brings strong expertise across business, clinical practice, and technology. This includes leadership with experience in major hospitals and global tech firms.

The opportunity for AI neurodevelopmental care in India is significant. The global market is estimated at USD 110 billion, growing at around 15% CAGR. Rising autism prevalence, increasing AI adoption, and a shortage of therapists are driving demand.

With strong early traction and institutional backing, Gabify is well placed to shape the future of digital neurodevelopmental care in India and beyond.